• Citer

COVAX – Time to reconsider the strategy and its target

par Bell, David;Brown, Garrett Wallace;Oyibo, Wellington;Ouédraogo, Samiratou;Tacheva, Blagovesta;Barbaud, Elena;Kalk, Andreas;Ridde, Valéry;Paul, Elisabeth
Référence Health Policy OPEN, page (100096)
Publication Publié, 2023-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.